Cutting through the noise: How biopharma is actually using AI to scale oncology research

AI is transforming how biopharma generates evidence, from extracting insights from complex clinical data to scaling analyses that were previously too resource-intensive to pursue. But as AI expands what's possible, high-quality, validated data becomes even more critical. In this panel, experts from across the industry will discuss how trusted data and scientific rigor are enabling responsible AI adoption and accelerating oncology research. Topics will include:

How high-quality, validated real-world data underpins trustworthy AI-enabled research
How transparent data validation is applied in practice to evaluate data quality and fitness for purpose
How biopharma teams are using AI to scale scientific analyses, uncover new insights, and extend researchers' capabilities

Register to hear how biopharma is putting AI to work in oncology, what it takes to use these technologies responsibly, and how trusted data can turn AI's potential into actionable evidence.

Chris Mader

Head of Strategy

Flatiron Health

Chris Mader leads the team responsible for Strategy at Flatiron Health, where he focuses on identifying and validating novel growth opportunities across our data, services, and point of care businesses. Prior to joining Flatiron Health in 2018, he held business development roles at Caris Life Sciences as well as prior scientific leadership roles in genomics and drug discovery at the Broad Institute of MIT and Harvard. Chris graduated from Yale University with a PhD in Cell Biology and received his bachelor's degree from the University of Notre Dame in Biological Sciences.

Country

Cutting through the noise: How biopharma is actually using AI to scale oncology research

Panelists

Moderator

Register for the webinar